Pfizer Knocks It Out of the Park With Its Q1 Results
Older drugs, including Lipitor and Lyrica, weighed on Pfizer's (NYSE: PFE) growth in recent years. But investors hoped that things would improve significantly after the big drugmaker spun off its Upjohn unit. They also expected that Pfizer's COVID-19 vaccine, developed with BioNTech, would turbocharge growth. And now, investors' wishes have been fulfilled.
Pfizer announced its first-quarter results before the market opened on Tuesday. Despite a blowout quarter, the pharma stock slipped a little in early trading. Here are the highlights from Pfizer's Q1 update.
Image source: Getty Images.
Source Fool.com
